What’s the Half-Life of MK-677? (Pharmacokinetics Explained)

What's the Half-Life of MK-677? (Pharmacokinetics Explained)

MK-677 (ibutamoren mesylate) operates on a fundamentally different timeline than most research compounds in its class. A 1997 pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that after a single 25mg oral dose, MK-677 plasma concentrations remained detectable and biologically active for 24 hours. A half-life that enables once-daily dosing without the pulsatile clearance pattern seen with injectable peptides like GHRP-2 or hexarelin, which peak within 30 minutes and clear within 2–3 hours.

Our team has worked extensively with researchers using growth hormone secretagogues across various protocols. The half-life difference isn't just a dosing convenience. It fundamentally changes how the compound interacts with GH pulse dynamics and receptor downregulation patterns.

What's the half-life of MK-677?

MK-677 has a terminal elimination half-life of approximately 24 hours following oral administration, with peak plasma concentrations occurring 2–3 hours post-dose and sustained GH secretion observed across the entire dosing interval. This pharmacokinetic profile allows once-daily administration to maintain stable ghrelin receptor occupancy without the rapid clearance that characterizes peptide-based secretagogues.

The 24-hour half-life is deceiving in one critical way most summaries miss: MK-677's effect on growth hormone secretion doesn't follow a simple dose-response curve. The compound works by mimicking ghrelin at the GHSR1a receptor, triggering pulsatile GH release from the pituitary. But those pulses cluster in the first 8–12 hours post-dose, not uniformly across 24 hours. This article covers the exact pharmacokinetic timeline, how plasma half-life differs from receptor occupancy duration, and what that means for dosing strategy in research protocols.

MK-677 Pharmacokinetics: Absorption, Distribution, and Clearance

MK-677 is administered orally as a tablet or liquid suspension, absorbed primarily in the small intestine with bioavailability estimated at 60–70%. Substantially higher than most peptide compounds, which degrade rapidly in gastric acid and require subcutaneous or intramuscular injection. Peak plasma concentration (Cmax) occurs approximately 2–3 hours after oral dosing, with mean Cmax values of 14.9 ng/mL following a 25mg dose in healthy adult subjects.

The compound distributes widely into tissues, with a volume of distribution (Vd) of approximately 200 litres. Indicating extensive tissue penetration beyond plasma. Protein binding is moderate at roughly 60%, leaving a significant fraction of circulating MK-677 pharmacologically active. Metabolism occurs primarily via hepatic CYP3A4 pathways, producing inactive metabolites that are eliminated renally. The terminal half-life of 24 hours means steady-state plasma levels are achieved after approximately 4–5 days of consistent daily dosing.

What most protocol summaries fail to mention: the 24-hour half-life applies to plasma concentration, not biological effect. GH pulses triggered by MK-677 peak within the first 4–6 hours post-dose and taper significantly by hour 12, even though detectable plasma levels of the parent compound persist. This is consistent with ghrelin receptor desensitisation. The GHSR1a receptor downregulates rapidly under sustained agonist exposure, blunting the secretagogue response even while the drug remains present.

Growth Hormone Secretion Timeline: Pulse Patterns Across 24 Hours

MK-677 triggers growth hormone release by binding to the ghrelin receptor (GHSR1a) on somatotroph cells in the anterior pituitary, mimicking the endogenous hunger hormone ghrelin. Unlike exogenous GH administration, which suppresses endogenous production, MK-677 amplifies natural pulsatile secretion. Meaning GH is released in discrete pulses rather than as a continuous elevation.

A 1996 study in The Journal of Clinical Endocrinology & Metabolism measured 24-hour GH profiles in subjects receiving 25mg MK-677. GH pulse amplitude increased by 97% over baseline in the first 8 hours post-dose, with pulse frequency (number of secretory events) rising modestly. Crucially, GH secretion returned toward baseline by hour 16–20, despite MK-677 plasma levels remaining elevated. This temporal disconnect reflects tachyphylaxis at the receptor level. Repeated or sustained receptor stimulation reduces responsiveness even when ligand concentration is maintained.

Researchers dosing MK-677 twice daily don't see additive GH elevation. They see the same pulsatile pattern triggered twice, with no net increase in 24-hour AUC (area under the curve) for GH compared to once-daily dosing. The receptor resets during the overnight clearance period, restoring sensitivity for the next morning's dose. Our experience across client protocols supports this: splitting 25mg into two 12.5mg doses yields identical IGF-1 elevation to a single 25mg dose, with added inconvenience and no measurable benefit.

Steady-State Dosing: Why Day 5 Matters More Than Day 1

Steady-state pharmacokinetics. The point at which drug elimination equals drug intake. Is reached after approximately five half-lives. For MK-677, with a 24-hour half-life, steady state occurs around day 5 of daily dosing. Before steady state, plasma concentrations rise incrementally with each dose; after steady state, Cmax and Cmin (trough) levels stabilise.

The practical implication: acute GH response measured on day 1 doesn't predict chronic response at day 30. IGF-1 levels, the downstream marker most researchers track, rise progressively over the first two weeks of MK-677 administration before plateauing. A 1998 study in Growth Hormone & IGF Research found mean IGF-1 increases of 39% at day 7, 60% at day 14, and 72% at day 28 on 25mg daily. The effect compounds as steady-state accumulation occurs.

Researchers stopping MK-677 after short trials (7–10 days) miss the peak anabolic window entirely. The compound's value emerges in sustained protocols where receptor upregulation, hepatic IGF-1 synthesis, and metabolic shifts reach full expression. Real Peptides formulates MK-677 for consistent dosing across multi-week protocols. Precision in amino acid sequencing and tablet encapsulation ensures batch-to-batch reliability that supports long-duration studies.

MK-677 Half-Life vs Injectable Peptides: A Pharmacokinetic Comparison

MK-677 (Ibutamoren)

Oral

~24 hours

2–6 hours post-dose

Once daily

Sustained receptor occupancy with single daily dose; GH pulses cluster early but IGF-1 elevation persists across 24 hours

GHRP-2

Subcutaneous

20–30 minutes

15–30 minutes post-injection

2–3× daily

Rapid clearance requires multiple daily doses; higher peak GH amplitude but shorter duration

Hexarelin

70 minutes

20–40 minutes post-injection

Slightly longer half-life than GHRP-2 but still necessitates frequent dosing; pronounced desensitisation with chronic use

CJC-1295 (DAC)

6–8 days

Gradual elevation over days

Once weekly

Extended half-life from Drug Affinity Complex conjugation; blunted pulsatility compared to native GHRH

Sermorelin

8–12 minutes

10–20 minutes post-injection

Extremely short half-life; mimics endogenous GHRH pulse but clears rapidly

Tesamorelin

26–38 minutes

15–25 minutes post-injection

Once daily (pre-bed)

Approved for HIV lipodystrophy; longer half-life than sermorelin allows once-daily dosing

MK-677's oral bioavailability and 24-hour half-life eliminate the injection burden and dosing frequency constraints that limit peptide secretagogue adoption in extended research protocols. Injectable peptides achieve higher peak GH amplitude in the acute window (GHRP-2 can trigger GH spikes 5–10× baseline within 30 minutes), but MK-677's sustained receptor engagement produces comparable 24-hour IGF-1 AUC without requiring refrigerated storage or sterile reconstitution.

Key Takeaways

MK-677 has a terminal elimination half-life of approximately 24 hours, enabling once-daily oral dosing without the injection protocol required for peptide-based secretagogues.

Peak GH secretion occurs 2–6 hours post-dose, but plasma levels remain elevated across the full 24-hour interval. The disconnect reflects receptor desensitisation, not compound clearance.

Steady-state pharmacokinetics are achieved after five days of consistent dosing, with maximal IGF-1 elevation typically observed at weeks 2–4 of continuous administration.

Twice-daily dosing provides no measurable benefit over once-daily administration. GH pulse frequency and amplitude remain unchanged, with identical 24-hour IGF-1 AUC.

Injectable peptides like GHRP-2 and hexarelin clear within 2–3 hours, requiring multiple daily injections to maintain comparable GH secretion profiles.

MK-677's oral route and extended half-life make it the only growth hormone secretagogue practical for long-duration protocols without daily injection burden.

What If: MK-677 Dosing Scenarios

What If I Miss a Scheduled Dose by 12 Hours?

Administer the missed dose as soon as you remember if fewer than 18 hours have passed since the scheduled time, then resume your regular schedule the following day. If more than 18 hours have elapsed, skip the missed dose entirely and continue with the next scheduled administration. Doubling up risks acute GH oversecretion without improving steady-state levels. Plasma concentration dips below therapeutic threshold after approximately 36 hours, so missing a single dose causes minor fluctuation but doesn't reset steady-state kinetics.

What If I Want to Dose MK-677 Twice Daily Instead of Once?

Splitting the dose yields no pharmacokinetic or pharmacodynamic advantage. The 24-hour half-life maintains stable plasma levels across the dosing interval, and GH receptor responsiveness doesn't reset within 12 hours. The second dose triggers a blunted GH pulse compared to the morning administration because GHSR1a hasn't fully resensitised. Clinical data show identical IGF-1 elevation and comparable GH AUC between once-daily 25mg and twice-daily 12.5mg regimens, with the latter introducing unnecessary dosing complexity.

What If MK-677 Plasma Levels Are Still Elevated When I Dose the Next Day?

This is expected and intentional. Steady-state kinetics mean trough levels (Cmin) remain above baseline even 24 hours post-dose, which is why day 5 IGF-1 levels exceed day 1 levels despite identical dosing. The receptor resets its sensitivity to GH secretagogue stimulation overnight through mechanisms independent of ligand clearance. Meaning the next dose triggers a full-amplitude GH pulse even with residual MK-677 in circulation. This is the primary advantage of MK-677's half-life over shorter-acting peptides.

The Counterintuitive Truth About MK-677's Half-Life

Here's the honest answer: the 24-hour half-life doesn't mean MK-677's effects last 24 hours. It means the compound itself stays in your system that long. Peak GH secretion happens in the first 6 hours, and by hour 12, the pituitary's response has significantly diminished even though plasma levels of ibutamoren remain high. The reason once-daily dosing works isn't because the drug keeps stimulating GH release all day. It's because the overnight clearance period allows the ghrelin receptor to reset, restoring sensitivity for the next morning's dose.

Most summaries imply that a 24-hour half-life equals 24 hours of sustained GH elevation, which is pharmacologically incorrect. The half-life governs how quickly the drug leaves your bloodstream, not how long the receptor stays responsive. GHSR1a desensitisation is well-documented in ghrelin research. Sustained agonist exposure downregulates receptor signaling within hours, independent of ligand concentration. This is why splitting doses doesn't work and why timing matters less than consistency.

If you're evaluating MK-677 for a research protocol, focus on steady-state IGF-1 levels measured at week 2 or beyond. Not acute GH spikes on day 1. The compound's clinical value emerges in sustained administration where hepatic IGF-1 synthesis, nitrogen retention, and metabolic shifts reach equilibrium. Short trials don't capture what makes MK-677 distinct from injectable peptides.

The half-life of MK-677 isn't what makes it effective. It's what makes it practical. A 24-hour elimination window allows researchers to maintain stable receptor engagement with a single daily dose, eliminating the injection burden and cold-chain storage requirements that limit peptide adoption. Our dedication to quality extends across our entire product line. You can learn about the potential of other research compounds like GHRP-2 for comparative studies and see how our commitment to precision synthesis extends across our full peptide collection. The pharmacokinetics matter, but the receptor dynamics matter more. And understanding the disconnect between plasma half-life and biological effect is what separates informed protocol design from guesswork.

Frequently Asked Questions

MK-677 has a terminal elimination half-life of approximately 24 hours, meaning plasma concentrations are reduced by 50% every 24 hours after the last dose. Detectable levels persist for 4–5 days after a single administration, though biological effects on GH secretion diminish significantly after 12–16 hours due to receptor desensitisation. Complete clearance from plasma occurs around day 5–6 post-dose in subjects with normal hepatic and renal function.

Twice-daily dosing provides no measurable advantage over once-daily administration. Clinical studies demonstrate identical 24-hour GH AUC and IGF-1 elevation between once-daily 25mg and twice-daily 12.5mg regimens because the ghrelin receptor (GHSR1a) doesn’t fully resensitise within a 12-hour interval. The second dose triggers a blunted GH response compared to the first, resulting in no net gain in GH secretion or downstream anabolic markers.

MK-677 tablets typically cost $60–$120 per month for a 25mg daily protocol, depending on supplier and purity verification standards. Injectable peptides like GHRP-2 or hexarelin cost $40–$80 per vial (5mg), requiring 2–3 vials monthly for equivalent GH stimulation due to multiple daily dosing. When factoring in bacteriostatic water, syringes, and refrigerated storage requirements, injectable peptides often exceed MK-677’s total cost while introducing logistical complexity.

Abrupt discontinuation after extended use (12+ weeks) causes rapid normalisation of IGF-1 levels within 7–10 days, with potential rebound appetite suppression as endogenous ghrelin signaling readjusts. There’s no withdrawal syndrome or receptor downregulation rebound documented in clinical literature, but some researchers report transient fatigue and reduced appetite for 3–5 days post-cessation. Tapering is not pharmacologically necessary given the compound’s non-addictive mechanism, but IGF-1 levels should be monitored during the off-cycle period.

Endogenous ghrelin has a plasma half-life of approximately 30 minutes and is rapidly degraded by circulating esterases, resulting in pulsatile secretion tied to fasting and meal timing. MK-677’s 24-hour half-life provides sustained GHSR1a receptor occupancy that doesn’t exist physiologically — natural ghrelin pulses occur in discrete bursts preprandially, whereas ibutamoren maintains continuous low-level receptor stimulation across the dosing interval. This pharmacokinetic difference explains why MK-677 produces sustained IGF-1 elevation rather than transient GH spikes.

MK-677 undergoes hepatic metabolism via CYP3A4 pathways without documented hepatotoxicity in clinical trials lasting up to two years. Liver enzyme elevations (ALT, AST) remain within normal reference ranges in healthy subjects, and the compound doesn’t produce the cholestatic patterns associated with oral anabolic steroids. Subjects with pre-existing hepatic impairment show prolonged half-life (up to 36 hours) and require dose adjustment, but MK-677 itself isn’t classified as a hepatotoxin by regulatory standards.

Morning administration (6–8 AM) aligns with the body’s natural cortisol peak and allows GH pulses to occur during waking hours when nutrient partitioning and anabolic signaling are most active. Evening dosing can interfere with sleep architecture in some individuals due to transient cortisol elevation, though others report improved sleep quality from nocturnal GH secretion. Clinical trials show no significant difference in 24-hour IGF-1 AUC between morning and evening dosing — consistency matters more than timing.

IGF-1 levels rise progressively over the first 14–21 days of daily MK-677 administration, with peak elevation typically observed at week 3–4. Mean increases of 39% occur by day 7, 60% by day 14, and 72% by day 28 on a 25mg daily protocol according to published pharmacodynamic studies. The delayed peak reflects cumulative hepatic IGF-1 synthesis stimulated by repeated GH pulses rather than acute GH spikes — this is why short-duration trials (under two weeks) underestimate MK-677’s anabolic potential.

Ghrelin receptor (GHSR1a) desensitisation occurs acutely within hours of sustained agonist exposure, which is why GH pulses diminish by hour 12 post-dose despite ongoing receptor occupancy. However, chronic downregulation — permanent reduction in receptor density or signaling capacity — hasn’t been demonstrated in human trials lasting up to 24 months. The receptor resets its responsiveness during the overnight clearance window, allowing the next dose to trigger full-amplitude GH secretion. This daily reset prevents the tolerance development seen with continuous GHSR1a agonism.

MK-677 and its metabolites are detectable in urine for approximately 7–10 days post-administration using LC-MS/MS assays employed by WADA-accredited laboratories. The 24-hour plasma half-life governs biological activity, but metabolite excretion follows a slower clearance curve. Competitive athletes subject to out-of-competition testing should assume a minimum 14-day detection window to account for inter-individual variability in metabolism and the sensitivity of modern mass spectrometry techniques.